Luminex Corp.

FREMONT, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences in November. Guggenheim Inaugural Healthcare Conference in Boston, MAFireside chat on Monday, November 11, 2024, at 11:00 a.m. Eastern Time UBS Global Healthcare Conference in Rancho Palos Verdes, CAPresentation on Wednesday, November 13, 2024, at 4:15 p.m. Pacific Time Interested parties may access a live and archived webcast of these presentations on the “Investors” section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@lages.com Investor Contact:Paul GoodsonHead of Investor Relationspgoodson@cytekbio.com

FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company’s growth, spearheading initiatives that improved operational processes and paving the way for Cytek’s future success. His leadership has been integral to enhancing the company's efficiency and laying a strong foundation for ongoing operational improvements. “We are grateful to Chris for his dedication and contributions to Cytek,” said Dr. Wenbin Jiang, CEO of Cytek. “As we look ahead, we believe this is an opportunity to streamline our organizational structure. By flattening our hierarchy, we aim to increase agility, empower our teams, and further drive operational efficiency.” “I have been fortunate to work with a talented and driven team in a growing industry,” said Williams. “I believe that Cytek is well-positioned for continued success and will thrive under this new structure.” Williams will remain with Cytek until September 27, 2024, to ensure a smooth transition and assist with the restructuring process. About Cytek Biosciences, Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding the Chief Operating Officer’s departure date and Cytek’s planned organizational restructure and its potential impact on Cytek’s business operations and future success. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to global economic, political and market conditions; competition; market acceptance of Cytek’s current and potential products; Cytek’s dependence on certain sole and single source suppliers; Cytek’s ability to manage the growth and complexity of its organization; Cytek’s ability to manage relationships with key customers and suppliers; Cytek’s ability to retain key employees; and Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Investor Contact: Paul GoodsonHead of Investor Relationspgoodson@cytekbio.com

To comply with academic institution guidelines, the founders' academic affiliations and roles are listed only at the end of the statement. BOSTON, Sept. 3, 2024 /PRNewswire/ -- Somite Therapeutics, a fully integrated TechBio company leveraging big data and AI to introduce novel cell replacement therapies, today announced a $4.8M extension of its pre-seed round, only 6 months after the initial raise, bringing total funds raised to over $10M. Continue Reading "With most of the funds still in the bank, we were not planning to fundraise until 2025," noted Dr. Micha Breakstone, Founder and CEO of Somite Therapeutics. "However, when Astellas Venture Management and Montage Ventures approached us, it was clear that they could add significant strategic value. Astellas Pharma and Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas, "AIRM") focus on regenerative medicine and cell therapy research in ophthalmology and other therapeutic areas that have few or no available treatment options, while Montage Ventures has built a robust thesis and has deep insights into this space, so we decided to extend the round." Somite Announces Round Extension with Astellas Venture Management and Montage Ventures Joining as Board Observers Post this The additional funding will be used to expedite data generation to train Somite's AI platform, AlphaStem, advance SMT-M01 toward the clinic, start a second clinical program, SMT-B01, using brown adipocytes to treat metabolic disorders, and begin research with hypoimmune cell lines. "We are thrilled to partner with Somite and support their innovative approach to AI-driven cell therapies," said Dr. Nagisa Sakurai, Senior Investment Manager at Astellas Venture Management, who will be joining Somite as a Board Observer. "Somite's work in vertically integrated AI-driven cell therapy aligns perfectly with Astellas' focus. We see great potential for impactful synergies between our companies." "Among numerous companies in the TechBio space, Somite stood out as the most aligned with our vision of AI-driven novel therapeutic modalities," said Dr. Daphne Che, who will also be joining Somite as a Board Observer. "We firmly believe that Somite will emerge as a leader in fully integrated AI-driven cell therapy." Additional investors joining the round include Nachum Shamir, former Chairman and CEO of Luminex, and Paul and Dr. Kendra Harris, a renowned clinician with extensive experience in clinical trials, who will also be joining Somite's Scientific Advisory Board. About Somite Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date. Somite Management Team: Micha Breakstone, PhD: CEO and Co-founder - Repeat AI entrepreneur (Chorus.ai acq. for $575m) Jonathan Rosenfeld, PhD: CTO and Co-founder - Head of the Fundamental AI group at MIT FutureTech Carl Morris, PhD: Chief Scientific Officer Kristy Brown, PhD: SVP Translational Development Shai Kivity, VP Strategy & Operations Scientific Co-founders: Olivier Pourquie, PhD: Professor of Genetics and Pathology, Harvard Medical School and Brigham and Women's Hospital Allon Klein, PhD: Professor of Systems Biology at Harvard Medical School Cliff Tabin, PhD: Chair of the Department of Genetics at Harvard Medical School Jay Shendure, PhD: HHMI Professor of Genome Sciences at University of Washington Media Contact: [email protected] Website: SOURCE Somite Therapeutics